People · Operator
Named in public records as an officer, director or promoter · active 2014–2014 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aurinia Pharmaceuticals Inc. | — | Biotechnology | Series C | $52.0M | $2.1B | 2014 |
Donald M. Wyatt at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Donald M. Wyatt on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kurt Von M. Emster | 1 | 1 |
| Benjamin M. Rovinski | 1 | 1 |
| Chris M. Kim | 1 | 1 |
| Stephen W. Zaruby | 1 | 1 |
| Michael M. Martin | 1 | 1 |
| Dennis M. Bourgeault | 1 | 1 |
| Daniel M. Park | 1 | 1 |
| Richard M. Glickman | 1 | 1 |
| Peter M. Wijngaard | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.